Potent inhibition of macrophage responses to IFN-gamma by live virulent Mycobacterium tuberculosis is independent of mature mycobacterial lipoproteins but dependent on TLR2.
Mycobacterium tuberculosis is a highly successful pathogen that can persist and cause disease despite an immune response. One potential mechanism for resisting elimination is by inhibiting the action of IFN-gamma. We have previously shown that live M. tuberculosis inhibits selected macrophage responses to IFN-gamma, and that purified M. tuberculosis 19-kDa lipoprotein inhibits induction of selected IFN-gamma-responsive genes through a TLR2-dependent pathway, whereas peptidoglycan inhibits responses to IFN-gamma by a TLR2-independent pathway. To determine the relative contribution of lipoproteins to the inhibition of responses to IFN-gamma, we deleted the M. tuberculosis gene (lspA) that encodes lipoprotein signal peptidase. This revealed that M. tuberculosis lipoprotein processing is indispensable for stimulation of TLR2 reporter cells, but that the lspA mutant inhibits macrophage responses to IFN-gamma to the same extent as wild-type bacteria. Macrophages lacking TLR2 are more resistant to inhibition by either strain of M. tuberculosis, suggesting that nonlipoprotein TLR2 agonists contribute to inhibition. Indeed, we found that phosphatidylinositol mannan from M. tuberculosis inhibits macrophage responses to IFN-gamma. M. tuberculosis inhibition of responses to IFN-gamma requires new protein synthesis, indicating that a late effect of innate immune stimulation is the inhibition of responses to IFN-gamma. These results establish that M. tuberculosis possesses multiple mechanisms of inhibiting responses to IFN-gamma.
Department of Medicine, Division of Infectious Diseases, New York University School of Medicine, New York, NY 10016, USA.
Niaz
N
Banaiee
Eleanor Z
EZ
Kincaid
Ulrike
U
Buchwald
William R
WR
Jacobs
Joel D
JD
Ernst
D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000235:genetics; D001426:Bacterial Proteins / Q000235:genetics / Q000502:physiology*; D002460:Cell Line; D015536:Down-Regulation / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000037:antagonists & inhibitors / Q000502:physiology*; D015850:Interleukin-6 / Q000172:deficiency / Q000235:genetics; D055666:Lipopeptides; D008074:Lipoproteins / Q000502:physiology*; D008264:Macrophages / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009154:Mutation; D009169:Mycobacterium tuberculosis / Q000201:enzymology / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity*; D010455:Peptides / Q000494:pharmacology; D010716:Phosphatidylinositols / Q000502:physiology; D051195:Toll-Like Receptor 2 / Q000819:agonists / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D014774:Virulence
D001426:Bacterial Proteins; D015850:Interleukin-6; D055666:Lipopeptides; D008074:Lipoproteins; C508075:Pam(3)CSK(4) peptide; D010455:Peptides; D010716:Phosphatidylinositols; C493486:Tlr2 protein, mouse; D051195:Toll-Like Receptor 2; C054977:phosphatidylinositol dimannoside; D007371:Interferon-gamma; D016282:Aspartic Acid Endopeptidases; C095652:signal peptidase II